Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Xencor Inc XNCR

Healthcare Biotechnology
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of... see more

Recent & Breaking News (NDAQ:XNCR)

Xencor Reports Third Quarter 2019 Financial Results

Business Wire November 5, 2019

Xencor to Host Third Quarter 2019 Financial Results Webcast and Conference Call on November 5, 2019

Business Wire October 29, 2019

Xencor to Present at the 2019 Cantor Global Healthcare Conference

Business Wire September 26, 2019

Xencor Appoints Celia Eckert as Vice President, General Counsel and Corporate Secretary

Business Wire September 10, 2019

Xencor Reports Second Quarter 2019 Financial Results

Business Wire August 6, 2019

Xencor to Present at Upcoming Investor Conferences

Business Wire August 1, 2019

Xencor to Host Second Quarter 2019 Financial Results Webcast and Conference Call on August 6, 2019

Business Wire July 30, 2019

Xencor Announces the Planned Retirement of Chief Medical Officer Paul Foster, M.D.

Business Wire June 27, 2019

MarketAxess Holdings Set to Join S&P 500; Axon Enterprise to Join S&P MidCap 400; Others to Join S&P SmallCap 600

PR Newswire June 24, 2019

Xencor Doses First Patient in Phase 1 Study of XmAb®22841 for the Treatment of Patients with Advanced Solid Tumors

Business Wire June 3, 2019

Xencor Appoints Jeremy Grunstein, Ph.D., as Vice President, Business Development

Business Wire May 23, 2019

Xencor Reports First Quarter 2019 Financial Results

Business Wire May 9, 2019

Xencor to Present at Upcoming Investor Conferences

Business Wire May 8, 2019

Xencor Doses First Patient in Phase 1 Study of XmAb®23104 for the Treatment of Patients with Advanced Solid Tumors

Business Wire May 6, 2019

Xencor to Host First Quarter 2019 Financial Results Webcast and Conference Call on May 9, 2019

Business Wire May 2, 2019

Xencor Announces Partial Clinical Hold Lifted on Phase 1 Study of XmAb®14045

Business Wire April 30, 2019

Xencor and Astellas Enter Collaboration for Novel Bispecific Antibody Program

Business Wire April 2, 2019

Xencor to Participate in Upcoming Investor Conferences

Business Wire April 1, 2019

Xencor Announces Closing of Research Collaboration and License Agreement with Genentech

Business Wire March 8, 2019

Xencor Reports Fourth Quarter and Full Year 2018 Financial Results

PR Newswire February 25, 2019